Drospirenone is also marketed (in combination with ethinylestradiol, EE) as the oral contraceptive Yasmin.
See under 'Oral Contraceptives' for other combinations of estrogens and progestins.
- TRADE NAME: Nextstellis (Mayne Pharma)
- INDICATIONS: Indicated for use by females of reproductive potential to prevent pregnancy.
- SYNONYM: DRSP (drospirenone); E4 (estetrol)
- CLASS: Antiandrogen, Estrogen, Hormone, Progestin/estrogen CHC
- HALF-LIFE: 27 hours (estetrol); 34 hours (drospirenone)
- FDA APPROVAL DATE: 04/15/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
bile acid sequestrants, CYP3A Inducers, CYP3A Inhibitors - PREGNANCY: Discontinue if pregnancy occurs.
- See adverse reactions attributed to class:
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
FEMALES OVER 35 YEARS OLD WHO SMOKE SHOULD NOT USE DROSPIRENONE/ESTETROL
CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVE USE.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
